| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-08-12 | Boehringer Ingelheim (Germany) Circuit Therapeutics (USA - CA) | obesity and associated diseases | collaboration R&D |
Metabolic diseases | Collaboration agreement | |
| 2015-08-12 | CMC Biologics (Denmark - USA) PATH Malaria Vaccine Initiative | monoclonal antibodies | malaria | development manufacturing production |
Infectious diseases - Parasitic diseases | Production agreement |
| 2015-08-12 | Cytos Biotechnology (Switzerland) Checkmate Pharmaceuticals (USA - MA) | CYT003, VLP platform, technology related to oligonucleotide synthesis | licensing |
Cancer - Oncology - Technology - Services | Licensing agreement | |
| 2015-08-12 | Sarepta Therapeutics (USA - MA) | nomination |
Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination | ||
| 2015-08-11 | Clovis Oncology (USA - CO) Genentech, a member of Roche Group (USA - CA - Switzerland) | atezolizumab (MPDL3280A; anti-PDL1) and rociletinib (CO-1686) | advanced EGFR-mutant non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-08-11 | Janssen Biotech, a J&J company (USA - NJ) Poseida Therapeutics (USA - CA) | Centyrin technology | multiple myeloma | R&D development licensing commercialisation |
Cancer - Oncology | Development agreement |
| 2015-08-11 | Crispr Therapeutics (Switzerland - UK) | nomination |
Nomination | |||
| 2015-08-10 | Intrexon (USA - MD) Synthetic Biologics (USA - MD) | biotherapeutics for the treatment of patients with phenylketonuria | phenylketonuria | Rare diseases - Genetic diseases - Metabolic diseases | Collaboration agreement | |
| 2015-08-10 | Immune Design (USA - MA) Merck&Co (USA - NJ) | Keytruda® (pembrolizumab - MK-3475), G100 and LV305 | non-Hodgkin’s lymphoma (NHL), melanoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-08-10 | Apeiron Biologics (Austria) Evotec (Germany) Sanofi (France) | small molecule-based immuno-oncology therapies | hematological cancers, solid tumors | R&D - research - development - licensing | Cancer - Oncology | Milestone |
| 2015-08-10 | Khondrion (The Netherlands) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-08-07 | Sanofi (France) Evotec (Germany) | beta cell modulating drugs, beta cell replacement therapy | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2015-08-07 | Horizon Pharma (Ireland) | nomination |
Nomination | |||
| 2015-08-07 | Paion (Germany) | nomination |
Nomination | |||
| 2015-08-06 | FibroGen (USA - CA) | nomination |
Nomination | |||
| 2015-08-06 | MabVax Therapeutics (USA - CA) The Rockefeller University (USA - NY) | HuMab 5B1 | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-08-06 | Stada (Germany) Gedeon Richter (Hungary) | biosimilar pegfilgrastim | neutropenia | licensing distribution |
Cancer - Oncology | Licensing agreement |
| 2015-08-06 | Epizyme (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-08-05 | AstraZeneca (UK) Mirati Therapeutics (USA - CA) | durvalumab (MEDI4736), in combination with mocetinostat | non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-08-05 | Aveo Oncology (USA - MA) Pharmstandard Group (Russian Federation) | tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) | all indications excluding ocular conditions | licensing development production manufacturing commercialisation |
Cancer - Oncology | Licensing agreement |
